Novartis raises guidance despite trial setbacks hitting profit

Novartis raised its guidance despite clinical trial setbacks weighing on profit. Q3 adjusted EPS came in at $2.46, beating the $2.27 estimate, while sales of $14.522B missed the $14.582B estimate.

Detected & updated continuously · Source: Nebula